MedTrace Logo

Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration

NCT03912220 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-06-12

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effects of a nutritional supplement called nicotinamide riboside in preventing small fiber nerve degeneration that is experimentally induced by applying capsaicin to skin in otherwise healthy study participants. Furthermore, the effects on nerve regeneration will also be evaluated. The results will be compared to a placebo control drug.

Conditions

  • Small Fiber Neuropathy

Interventions

DRUG

Nicotinamide riboside

The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.

DRUG

Placebo Oral Tablet

Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.

Sponsors & Collaborators

Principal Investigators

  • Ahmet Hoke · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2023-05-01
Completion
2023-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03912220 on ClinicalTrials.gov